Tryptamine Therapeutics (AU:TYP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics has announced the departure of Peter Molloy from its board of directors, effective November 8, 2024. Molloy held a significant number of shares and options in the company, which are escrowed for 24 months. This change could impact investor sentiment as the company navigates its strategic direction without Molloy.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.